Compare Open Text Corporation (OTEX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Open Text Corporation vs Sana Biotechnology Inc — how do they compare? Open Text Corporation trades at $22.41 (market cap $5.54B), while Sana Biotechnology Inc trades at $3.13 (market cap $879.40M). The key difference: Open Text Corporation is far larger — about 6.3× Sana Biotechnology Inc's market cap, and Open Text Corporation pays a 4.83% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| OTEX | SANA | |
|---|---|---|
Market Cap | $5.54B | $879.40M |
Sector | Technology | Health |
52-Week High | $39.69 | $5.92 |
52-Week Low | $20.01 | $2.68 |
Enterprise Value | $10.70B | $853.59M |
Dividend Yield | 4.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Open Text Corporation (OTEX) trades at $23.33, up 0.26% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.01 surpassing expectations. Fundamentals show a P/E of 11.32 and net income margin of 9.91%, while recent news highlights a $105 million investment in European AI and cloud expansion.
The outlook for OTEX is positive, supported by value-oriented valuation, consistent earnings outperformance, and strategic investments in AI. Key risks include competitive pressures in software and execution of growth initiatives. Analyst consensus suggests a 30.7% upside to the $29.75 price target, with 42% of ratings being Buy.
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
